This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany
Blood Cancer Journal Open Access 29 October 2021
-
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
Leukemia Open Access 18 February 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Siegel RL, Miller KD, Jemal A . Cancer statistics, 2017. CA Cancer J Clin 2017; 67: 7–30.
Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998; 338: 1506–1514.
Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C . Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575.
Rozman C, Montserrat E, Rodríguez-Fernández JM, Ayats R, Vallespí T, Parody R et al. Bone marrow histologic pattern—the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–648.
Langenmayer I, Nerl C, Knauf W, Adorf D, Hallek M, Dietzfelbinger H et al. Interferon alpha 2b in the treatment of early stage CLL with risk for progression. Results of a randomized multicenter study. Br J Haematol 1996; 94: 362–369.
Johnson S, Smith AG, Löffler H, Osby E, Juliusson G, Emmerich B et al. Multicentre prospective randomised trial of fludarabine versus cyclophophamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996; 347: 1432–1438.
Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319–2325.
Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750–1757.
Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. The French Cooperative Group on Chronic Lymphocytic Leukemia. Blood 1990; 75: 1414–1421.
Schweighofer CD, Cymbalista F, Müller C, Busch R, Porcher R, Langerbeins P et al. Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage a chronic lymphocytic leukemia – first results of a randomized German-French cooperative phase III trial. Blood 2013; 122: 524.
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009; 114: 3382–3391.
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885–891.
Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007; 370: 230–239.
Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007; 25: 793–798.
Acknowledgements
We thank Anne Westermann, Ute Elberskirch, Anna Fink, Thu-Trang Pham and Katrin Klein for their contribution to this work. The trial was supported by grants from Deutsche Krebshilfe (German Cancer Aid) (70–2434 and 106116), Wilhelm-Sander-Foundation (2001.004.1 and 2001.004.2), and BayerSchering Pharma AG.
Disclaimer
Study drug was provided by BayerSchering Pharma AG, which did not have a role in the design or conduct of the study, writing of the manuscript, or the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
This paper was presented in part at the 49th annual meeting of the American Society of Hematology, Atlanta, GA, USA, 8 December 2007.
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Hoechstetter, M., Busch, R., Eichhorst, B. et al. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia 31, 2833–2837 (2017). https://doi.org/10.1038/leu.2017.246
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2017.246
This article is cited by
-
Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany
Blood Cancer Journal (2021)
-
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
International Journal of Hematology (2020)
-
Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm
Current Hematologic Malignancy Reports (2020)
-
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial
Leukemia (2020)
-
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group
Leukemia (2020)